Enbrel and etanercept biosimilars: a tale of two patent systems-Reference-Cited by-同舟云学术

Enbrel and etanercept biosimilars: a tale of two patent systems

Published:2017-01 Issue:1 Volume:6 Page:5-7
ISSN:2046-8954
Container-title:Pharmaceutical Patent Analyst
language:en
Short-container-title:Pharmaceutical Patent Analyst

Author:

Norman Peter¹

Affiliation:

1. Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK

Publisher

Future Science Ltd

Subject

General Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/ppa-2016-0043

Reference12 articles.

1. Immunex Corp. EP0418014 (1991).

2. Biogen Press Release 16 January 2016. http://media.biogen.com/press-release/biosimilars/benepali-first-etanercept-biosimilar-referencing-enbrel-approved-european-

3. Immunex Corp. USRE36755 (2000).

4. Hoffman La Roche, Inc. US8063182 (2011).

5. Hoffman La Roche, Inc. US8163522 (2012).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds;Biomedicine & Pharmacotherapy;2024-09

2. Polyvalency: an emerging trend in the development of clinical antibodies;Drug Discovery Today;2024-01

3. Production of recombinant human tumor necrosis factor receptor- IgG1 Fc domain fusion protein expressed by genetically CHO- DG44 cells;Journal of Cellular Biotechnology;2022-09-20

4. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology;Journal of the American Academy of Dermatology;2020-08

5. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis;Current Rheumatology Reports;2018-11-09